Huc1-394

Phase 2

HHuons Co., Ltd.

Huc1-394 is one of 4 therapeutic programs targeting Dry Eye Disease (DED). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Dry Eye Disease (DED)Recruiting

Dry Eye Disease (DED)Phase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Dry Eye Disease (DED)

#DrugCompanyPhaseTrials

Propylene Glycol

TThe Cleveland Clinic

Approved

1 2

Huc1-394

HHuons Co., Ltd.

Phase 2

1 3

DFL24498

DDompé Farmaceutici S.p.A

Phase 2

1 4

Licaminlimab

OOculis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Dry Eye Disease (DED)

NCT07656688

Clinical

Trials by Indication[1]

Dry Eye Disease (DED)1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of HUC1-394 in Participant With Dry Eye Disease

Recruiting·HHuons Co., Ltd.·Phase 2·NCT07656688·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Huc1-394. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Huc1-394. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Huons Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: HHuons Co., Ltd.

Huc1-394

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Dry Eye Disease (DED)1 trial

References

Drug Info

Quick Facts

Related News